|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM061805084 |
| 003 |
DE-627 |
| 005 |
20250128073501.0 |
| 007 |
tu |
| 008 |
231221s1983 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0206.xml
|
| 035 |
|
|
|a (DE-627)NLM061805084
|
| 035 |
|
|
|a (NLM)6203380
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Maru, A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prophylactic and chemotherapeutic efficacy of pivmecillinam (PMPC) against infections after TUR-P and prostatectomy
|
| 264 |
|
1 |
|c 1983
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.07.1984
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The prophylactic and chemotherapeutic efficacy of PMPC against infections after TUR-P has been investigated. Bacteriological evaluation: PMPC , 200-300 mg/day for 2-12 weeks, was administered to 49 patients, who had over 10(3)CFU/ml of microorganisms after CET or CEC treatment for 3-7 days. The eradication rate of microorganisms was 40.8% after 2 weeks, 52.2% after 4 weeks, 64.1% after 6 weeks, 65.0% after 8 weeks and 70.6% after 12 weeks. Effectiveness on pyuria : The improvement rate of pyuria against 59 patients who had over 10(5)/hpf of pyuria , was 15.3% after 2 weeks, 16.4% after 4 weeks, 25.4% after 6 weeks, 58.5% after 8 weeks, 72.7% after 10 weeks and 75.0% after 12 weeks. Overall clinical efficacy on PMPC was examined in 26 patients. The results of efficacy were 27.3% after 2 weeks, 48.0% after 4 weeks, 50.0% after 6 weeks, 69.2% after 8 weeks, 75.0% after 10 weeks and 77.0% after 12 weeks. The clinical response was evaluated according to a criterion for clinical evaluation of antimicrobial agent on chronic complicated UTI proposed by UTI committee in Japan. No severe adverse effect including allergic reaction was found. Following administration of PMPC , three patients experienced adverse gastric reactions, and drug administration was discontinued at week 6 or 8. PMPC was effective as a prophylactic chemotherapeutic drug against infections after TUR-P and prostatectomy
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Amdinocillin Pivoxil
|2 NLM
|
| 650 |
|
7 |
|a 1WAM1OQ30B
|2 NLM
|
| 650 |
|
7 |
|a Penicillanic Acid
|2 NLM
|
| 650 |
|
7 |
|a 87-53-6
|2 NLM
|
| 700 |
1 |
|
|a Mitsuhashi, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shiba, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohashi, N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fujieda, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nishida, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okoshi, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kusakai, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Amino, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kaneda, T
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 29(1983), 2 vom: 30. Feb., Seite 245-53
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:29
|g year:1983
|g number:2
|g day:30
|g month:02
|g pages:245-53
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 29
|j 1983
|e 2
|b 30
|c 02
|h 245-53
|